Clean Meat Market: iPSC-Derived “Clean Meat” Attracts Billionaires

Lab-grown meat is fast becoming an alternative to its farm-grown counterpart as billionaire entrepreneurs and industry heavyweights invest into start-ups from across the nascent field of cellular agriculture. Produced via stem cells derived from cows, pigs, fish, or sheep, the emerging clean meat industry has the potential to transform the global food market and create a new trillion dollar industry in the process. Backed by investors like Bill Gates and Richard Branson, a projected 60% of meat will be created from muscle cells grown within bioreactors by 2040. These products will be sold in stories under names such as cultured meat, clean meat, and lab-grown meat.

Professional Course on Preservation of Cellular Therapies – May 18-19, 2021

Preservation of Cellular Therapies is a professional short course designed to provide practical training for those individuals involved in the preservation of cellular therapies. Hosted virtually over May 18-19, 2021, this course is associated with the Biopreservation Core Resource at the University of Minnesota. Come learn about fundamentals of preservation, protocol development, design of a storage facility, regulatory issues associated with preservation of cell therapies, clinical issues and more.

World first: TreeFrog Therapeutics announces the production of a single batch of 15 billion iPS cells in a 10L bioreactor with exponential amplification of 276-fold per week

Bordeaux, France, April 13th, 2021 – French cell therapy company TreeFrog Therapeutics announces unprecedented exponential growth of human induced pluripotent stem cells (hiPSC) in a 10L bioreactor. Using proprietary C-Stem™ technology, TreeFrog Therapeutics amplified 50 million hiPSC into a single batch of 15 billion cells in 6.5 days, and company reports exceptional cell quality. Data will be presented at the International Society for Stem Cell Research (ISSCR) Virtual Meeting, taking place June 21–26, 2021.

Cytonome cell sorter aids in Parkinson’s treatment

Cell sorting technology leader and innovator Cytonome-ST, LLC, has assisted pharmaceutical firm Sumitomo Dainippon Pharma Co., Ltd. to produce enough human stem cells to proceed with a clinical trial of a new treatment aimed at curing Parkinson’s Disease. Cytonome has developed the most advanced parallel microfluidic cell sorting and cell handling technologies in the world and produces the GigaSort® GMP cell sorting platform, the only parallel microfluidic cell sorter capable of effectively processing the large volumes required of cellular therapeutics in a gentle and efficient manner.

5 Strategies To Stay on Top of a Changing Cell Therapy Industry

As operations for cell and gene therapy programs become more demanding and supply chain management becomes more complex, your program may face challenges adapting to these changes. For example, increasing manufacturing and procedure volumes in combination with new and changing protocols will require the use of more automated, flexible and efficient processes. Tightening regulations will require greater documentation and process control. As cell and gene therapies continue to grow in clinical application, payers, study sponsors, and other agencies will require more data and reporting.

denovoMATRIX Launches New Enabling Technology for High-Quality Induced Pluripotent Stem Cell Culture

Dresden, Germany, March 22, 2021 — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, has announced the launch of a new range of products for the expansion, banking and maintenance of induced pluripotent stem cells (iPSC). The product line, termed myMATRIX iPSC, are chemically defined, ready-to-use consumables, designed to simplify and accelerate iPSC culture.

Vitro Biopharma Receives FDA Authorization to Conduct a Clinical Trial Using AlloRx Stem Cells® to Treat COVID-19

Golden, Colorado, April 6, 2021 — Vitro Biopharma has announced receipt of FDA authorization and clearance to enroll patients in its phase I-IIa, randomized, double-blinded, placebo controlled study of the safety and efficacy of therapeutic treatment with AlloRx Stem Cells® in adults with COVID-19. Its Investigational New Drug (IND) application will investigate the clinical effects of AlloRx Stem Cells® by studying safety and efficacy in patients with moderate to severe COVID-19.

Celularity Announces Fast Track Designation by the FDA for our Natural Killer Cell Therapy CYNK-001 in the Treatment of Recurrent Glioblastoma Multiforme

Florham Park, NJ, March 18, 2021 — Celularity Inc., a clinical-stage biotech company leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, announced the company has received Fast Track Designation from the U.S. FDA for its non-genetically modified cryopreserved human placental hematopoietic stem cell-derived NK cell therapy, CYNK-001, for the treatment of adults with recurrent glioblastoma multiforme (GBM). CYNK-001 is currently being investigated in multiple clinical trials, including a Phase 1 clinical trial for GBM.

Organicell and The Centers for Disease Control and Prevention Enter Into Agreement To Conduct Research on Influenza Viruses of Pandemic Potential

March 23, 2021, Miami, Florida — Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, has entered into a Material Cooperative Research and Development Agreement with the Centers for Disease Control and Prevention (“CDC”) to determine the anti-inflammatory and anti-infective effectiveness of Zofin™ in experimental models of influenza infection.

Shoreline Biosciences Raises $43M to Advance iPSC-derived Cellular Immunotherapies

Shoreline Biosciences, a California-based start-up specializing in iPSC-derived cellular immunotherapies for cancer and other serious diseases, has completed an impressive $43M funding round. Founded in 2020 in La Jolla, CA, the company is developing a pipeline of induced pluripotent stem cell (iPSC) derived NK cell and macrophage cell therapy product candidates. The company joins an impressive list of pioneers who are forging the path toward iPSC-derived cell therapeutics.

NeoProgen Receives First Granted Patent for Method to Treat Cardiac Conditions using Neonatal Heart-derived Medicinal Signaling Cells (nMSCs) and/or their Secretomes/Exosomes from US Patent Office

April 12, 2021, Baltimore, MD – NeoProgen, Inc., a pre-clinical stage company developing an exosome-based product from human neonatal heart-derived Medicinal Signaling Cells (nMSCs) for tissue repair and regeneration for the treatment of heart failure (HF) and other inflammatory diseases, announced that it has received a patent from the U.S. Patent Office Patent No.: US 10.967,007 B2 “Cardiac Stem Cells for Cardiac Repair”. The innovation was developed by Dr. Sunjay Kaushal, a pediatric cardiac surgeon, while he was at the University of Maryland, Baltimore. NeoProgen is the exclusive licensee of the newly issued patent.

Century Therapeutics Raises $160M for iPSC-derived CAR-T and CAR-NK Cell Therapeutics

Century Therapeutics has made waves by raising $160 million in Series C financing. This is on top of the existing $250 million that the company raised during a Series A round in 2019, bringing its total financing to an impressive $410 million. The Series C financing round was led by Casdin Capital, a New York-based investment firm. The company’s iPSC-derived CAR-expressing natural killer (NK) and T-cell therapeutics are on track to enter clinical trials for hematological and solid cancers in 2022.

Matica Biotechnology, Inc. Announces Groundbreaking for New GMP Facility

Matica Biotechnology, a CDMO specializing in clinical and commercial production of cell and gene therapies, has broken ground on its new 25,000 sq. ft. facility which will house its GMP virus production suites, development laboratories and company offices. The new building will be located at Providence Park in College Station, Texas. Matica Bio’s GMP facility is scheduled to open in Q3 2021 utilizing a bioreactor-based platform, with access to GMP production slots beginning in early 2022.

The New CO.DON Plant for the EU-approved Advanced Therapy Cartilage Regeneration Treatment Sets a Milestone in Cell Therapy for Commercial Manufacturing

Human cell experts from Germany’s CO.DON AG are again cutting the edge: they have launched human cells production on an industrial scale. The demanding quality standards required of the manufacturing conditions for human cell transplants led to the development of Integrated Isolator Technology (IIT) alongside industrial partners, which went into operation at CO.DON´s Teltow site in 1999. Now CO.DON has taken the next step using their experience as human cell experts: A plant for the industrial-scale production of human cells in Leipzig.

AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy

SEATTLE, March 2, 2021 — AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced plans for the expansion of their Cell and Gene Therapy Center of Excellence in Milan, to increase capacities and implement viral vector suspension capabilities. The new facilities are scheduled to begin full operation in 2022.

Organicell And Oklahoma State University Enter Into Agreement To Study Zofin™ In Respiratory Diseases Caused By Virus Infections Of Pandemic Potential

Miami, FL (April 14, 2021) – Organicell Regenerative Medicine, Inc. (OTCMKTS: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, has entered into an agreement with Oklahoma State University to evaluate Zofin™ for the treatment of respiratory diseases caused by virus infections of pandemic potential. This study site follows the Company’s earlier announcement of the agreement reached with the Centers for Disease Control and Prevention (“CDC”) to conduct research to determine the anti-inflammatory and anti-infective effectiveness of Zofin™ in experimental models of influenza infection.

How the MSC Market is Coming of Age in 2021

MSCs are of intense therapeutic interest because they represent a population of cells that have the potential to treat a wide range of acute and degenerative diseases. MSCs are advantageous over other stem cells types for a variety of reasons. In recent years, human mesenchymal stem cells (hMSCs) have become a foundational technology for several types of cell-based products. They are now being tested in a record numbers of trials as cell therapies, gene therapies, tissue-engineered products, and combination products. 

Global Market for iPSCs by Biomedical Application

Globally, companies have deployed an impressive range of business models for exploiting iPSC technology platforms. To date, iPSCs have found applications within academic research, drug discovery, toxicology testing, cell therapy, personalized medicine, disease modelling, industrial-scale manufacturing, biobanking, clean-meat production, and beyond.

How Human iPSCs are Revolutionizing Drug Discovery in 2021

Drug discovery involves high cost and uncertain outcomes.  Only a few companies can take the risk of investing enormous amounts of money into research and testing, only to see undesirable side effects emerge during the final human clinical trials. Now, some medicines are being tested for safety on specialized cells developed from human pluripotent cell lines. Cells types which are frequently being using within drug discovery include heart (cardiomyocytes) and liver cells (hepatocytes), which are the organs where 80% of drug failures occur.

CAR-T Cell Companies Proliferate: List of CAR-T Companies Worldwide

Continuously updated, this global list of CAR-T companies keeps expanding as new competitors enter the global marketplace. CAR-T cell therapy is as a type of immunotherapy that teaches T cells to recognize and destroy cancer. Read on to learn more about innovative CAR-T cell therapy companies and the novel technologies they are using to fight cancer.

[SALE] Database of Cell and Gene Therapy CMOs and CDMOs (2021)

Featuring nearly a hundred-companies worldwide, this is the world’s only database of cell and gene therapy CDMOs that is publicly available and continuously updated. If you are a cell therapy developer, use it to identify potential manufacturing partners. If you are a contract manufacturer, use it to identify the depth and breadth of your competition. With the competitive nature of this global market, you don't have the time to do the research. Claim this database to become immediately informed, without sacrificing hours of unnecessary research or missing critical opportunities. Act fast, because for a limited-time you can claim it for 20% off. 

[JUST RELEASED] Global Exosome Market – Market Size, Forecast, Trials and Trends, 2021

Released April 15, 2021, BioInformant has published a 274-page global market report that reveals the surging demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies. Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection. 

To access other market insights about CAR-T, MSCs, iPSCs, Cord Blood, Regenerative Medicine, and beyond, explore the BioInformant Shop.

*Want to advertise in this newsletter? Contact us at Info@BioInformant.com.